On paper, every acquisition moves “the business.” In medtech, the real question is which regulated artifacts move: establishment role, device listing/registration, DMR/DHF, supplier quality agreements, complaint history, and commercial contracts. Get that map wrong and you buy revenue you cannot legally ship—or you inherit a QMS remediation you did not price. This page is a practitioner’s lens: shapes of deals, what diligence is actually doing, and how sellers compress uncertainty before LOI.
Prefer a marketplace-first walkthrough (buy, sell, partner, deal shapes)? Start on Medical device acquisitions on Deal Desk. This page stays focused on diligence and integration mechanics.
You acquire equity (or substantially all assets) of the legal entity holding QMS scope, registrations, contracts, and people. Best when value is entangled across portfolio, shared services, and brand. Failure modes: inherited environmental/employment issues; bloated SGA; legacy ERP; “we will fix quality post-close” denial; founder reliance with no retention plan.
You buy a defined commercial line—SKUs, inventory, channel contracts, and the technical documentation stack that supports only those SKUs. Best when the seller remains a going concern. Failure modes: ambiguous split of shared sterilization validation; batch records that reference a site you are not buying; IT systems that cannot separate lot genealogy; a TSA priced like a favor instead of a scoped service.
Often IP + documentation + select inventory—sometimes without the commercial team. Best when the buyer already owns sales, labeling, and QMS capacity. Failure modes: underestimating re-validation, relabeling, establishment updates, and the time to re-train the field on a device they did not launch originally.
If you are debating shape, walk through company for sale vs line framing and the exit options comparison before you hire a code-name for the project.
Translate these into IC slides—these are the questions that survive a skeptical medical director or VP RA:
Earnouts tied to revenue are common—and commonly litigated when labeling changes, supply disruption, or buyer portfolio conflicts depress sales. If you accept milestones, tie them to measurable regulatory or commercial events both sides control, and define accounting and channel policies explicitly. Your counsel drafts language; operationally, you need a boss-level owner for the synergy case.
Does public posture match private files? Any open submissions, promises made to regulators, or audit observations still in remediation?
Can COGS hold at credible volume— or is there hidden CapEx (new line, sterilizer, packaging validation)?
Will the SKU ride a channel the buyer already funds—or does every sale require a new commercial muscle?
Who signs batch release, who owns complaints, who knows the DHF—are they contracted through close?
These are live buyer interests—not generic blog examples. Open any card to see the public-facing mandate.
A commercially credible wound-care listing for teams that can expand regional market access faster than the current owner can justify internally.
View details →A practical procedural-kit opportunity for operators that already know how to move sterile disposables through specialist channels.
View details →A mature but under-prioritized ambulatory monitoring line that could become strategically meaningful under a more focused owner.
View details →A rights-led women’s health opportunity suited to partners that already understand specialist office adoption and regional channel buildout.
View details →A strategic-options mandate around a credible decentralized diagnostics platform with stronger upside under a focused scale plan.
View details →Buyers: post a mandate. Sellers: list or respond with a workspace-backed profile—both sides reduce noise.
These pages cross-link intentionally—follow the path that matches your mandate, then return to the live board when you are ready to act.
Long-form guide: acquisition & distribution mechanics (with regulatory citations)
When the buyer only wants defined SKUs, regulatory files, and supply contracts—and the seller can legally separate them without starving the remainder. Line deals can close faster, but they collapse when shared QMS scope, facilities, ERP lot history, or IP licenses cannot be split cleanly. Model the TSA before you celebrate the LOI.
Incomplete DMR/DHF access, unresolved vigilance signals, software ownership or OTA policy gaps, sole-source suppliers who will not support transfer, promotion that outruns labeling, and ‘surprise’ CAPA backlogs. Buyers assume every late surprise has a little sibling you have not found yet.
Lead with a tight facts package that makes valuation credible. Mystery discounts price and extends escrow. Staged disclosure sequences risk—it does not mean hiding reportable events from serious parties under NDA.
Buyers test verification/validation traceability, cybersecurity maintenance, update policy, and whether the seller’s QMS actually governed the software lifecycle. If software was built outside the quality system, expect remediation scope in the integration plan.
Indemnities for regulatory misstatements, quality system breaches, and undisclosed enforcement tend to drive escrow size and survival periods—often alongside R&W insurance on larger deals. Your counsel maps specifics; operationally, the goal is a disclosure schedule that matches reality.